Reported 2 months ago
Cathie Wood, CEO of Ark Invest, continues to strategically buy stocks despite a challenging year for her funds. Recently, she added to her positions in Guardant Health, Oklo, and CRISPR Technologies. Guardant Health has seen solid performance with promising products in the oncology field, while Oklo aims to disrupt clean energy with its nuclear technology. CRISPR continues to innovate in gene editing, presenting long-term potential despite current lower stock prices. These moves reflect Wood's conviction in these companies' future growth.
Source: YAHOO